Your browser is no longer supported. Please, upgrade your browser.
TScan Therapeutics, Inc.
Index- P/E- EPS (ttm)-1.79 Insider Own6.00% Shs Outstand23.59M Perf Week0.00%
Market Cap206.85M Forward P/E- EPS next Y-4.50 Insider Trans1.05% Shs Float8.75M Perf Month6.19%
Income-42.20M PEG- EPS next Q-0.66 Inst Own66.60% Short Float0.59% Perf Quarter-1.80%
Sales8.10M P/S25.54 EPS this Y-91.30% Inst Trans371.92% Short Ratio0.73 Perf Half Y-
Book/sh7.38 P/B1.19 EPS next Y76.70% ROA- Target Price21.67 Perf Year-
Cash/sh7.71 P/C1.13 EPS next 5Y- ROE- 52W Range6.06 - 14.71 Perf YTD-16.67%
Dividend- P/FCF- EPS past 5Y- ROI61.70% 52W High-40.52% Beta-
Dividend %- Quick Ratio8.20 Sales past 5Y- Gross Margin- 52W Low44.39% ATR0.71
Employees90 Current Ratio8.20 Sales Q/Q700.00% Oper. Margin- RSI (14)54.32 Volatility11.07% 8.69%
OptionableNo Debt/Eq0.00 EPS Q/Q-120.90% Profit Margin- Rel Volume0.06 Prev Close8.73
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume70.57K Price8.75
Recom1.70 SMA201.65% SMA509.97% SMA200-0.48% Volume4,465 Change0.23%
Nov-11-21 07:00AM  
Nov-10-21 07:00AM  
Nov-04-21 09:30AM  
Nov-01-21 09:11AM  
Oct-19-21 02:43PM  
Oct-15-21 10:56AM  
Oct-05-21 07:00AM  
Sep-28-21 07:00AM  
Sep-09-21 04:05PM  
Sep-02-21 07:00AM  
Aug-19-21 07:00AM  
Aug-16-21 09:58AM  
Jul-15-21 06:59PM  
TScan Therapeutics, Inc., a preclinical-stage biopharmaceutical company, focuses on developing a pipeline of T cell receptor-engineered T cell, or TCR-T, therapies for the treatment of patients with cancer. It is developing TSC-100 and TSC-101 for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation; and TSC-200, TSC-201, TSC-202, and TSC-203 for the treatment of solid tumors. The company has a collaboration and license agreement with Novartis Institutes for Biomedical Research, Inc. to discover and develop novel TCR-T therapies. TScan Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
ZDRAVESKI ZORANChief Legal OfficerSep 23Buy7.484,71635,2554,716Sep 27 05:22 PM
Silver Brian M.Chief Financial OfficerSep 21Buy6.325,00031,58511,885Sep 22 06:51 PM
MacBeath GavinChief Scientific OfficerSep 21Buy6.195735349,767Sep 22 06:48 PM
MacBeath GavinChief Scientific OfficerSep 20Buy6.224,94330,74449,710Sep 22 06:48 PM